$OTLK - Outlook Therapeutics: one-drug biotech, FDA decision July 29, ~1 quarter of cash. Binary setup DD.

Outlook Therapeutics (OTLK) is a one-drug biotech. The drug is LYTENAVA, an eye-injection version of bevacizumab for wet AMD, a leading cause of vision loss in older patients. The whole company resolves to a single date: July 29, 2026, the FDA's PDUFA decision on the resubmitted application. Approval and rejection are both plausible, and there isn't much middle ground.

This is the fourth time around. The FDA issued Complete Response Letters (formal notices declining to approve and asking for more) three times already, in Aug 2023, Aug 2025, and Dec 2025.

The first cited manufacturing and evidence gaps; the later two followed the NORSE EIGHT confirmatory trial missing its primary endpoint in Nov 2024.

In May 2026 the FDA's Office of New Drugs granted the company's appeal, concluded substantial evidence of effectiveness *is* established, and said no further trials are required, leaving final labeling as the only open item. So the July 29 decision is closer to a labeling sign-off than a fresh efficacy

verdict. That's a genuine reversal, and it's why the stock is alive.

Stock is up \~35% today because the FDA accepted the resubmission for review. Note that acceptance isn't approval.

# The balance sheet

As of March 31, 2026:

* Cash $7.75M against quarterly burn of $7.83M (about one quarter of runway).
* Going concern flag from the auditor, present on every filing since at least Sep 2025.
* $27M debt across two promissory notes at prime +3% (9.5% floor) with 7.5% exit fees. The current portion alone ($15.8M) exceeds cash on hand.
* \~$18M working capital deficit, $633M accumulated deficit, no history of profit.
* Missed a required $3M quarterly debt-reduction payment in Dec 2025, triggering a 10% penalty and resetting a conversion floor to $0.404.

Share count went from \~33.6M to 104.6M in twelve months, so a holder from a year ago now owns roughly 32% of what they did. Three raises in 2026 at $2.51, $0.31, and $0.59, each lower than the last, plus a 67% cut to warrant strike prices to close a single institutional deal. More dilution before and after July 29 looks near-certain.

# The bull case if approved

* LYTENAVA would be the only FDA-approved ophthalmic bevacizumab, in a market where off-label compounded versions are \~34% of a US anti-VEGF market the company pegs at $8.5B.
* 12 years of regulatory exclusivity.
* Already approved and launched in Germany and the UK, so the regulatory case is partly de-risked.

# The chart

Up \~875% off the March low of $0.198 to around $1.57. Extended after a near-vertical move on a single event, including a 346M-share session. The pullback since June 12 is on lighter volume, which reads more like digestion than reversal, but it's stretched either way.

# Insider buying

6 open-market buys, 5 insiders, zero sells over twelve months. The largest was Sukhtian / GMS Ventures (a director and 10%+ owner) at \~$5M ($0.59) in late May, with other directors buying in the $0.43–0.83 range.

# Bottom line

This is a binary event with a known date. A rejection wouldn't necessarily kill the company, but with one quarter of cash, a going concern flag, and $27M of debt due by year-end, a fourth rejection would likely mean a wipeout-level raise, a distressed restructuring, or worse for current equity holders.

An approval would result in a rerate, OTLK becomes the sole holder of the only FDA-approved on-label ophthalmic bevacizumab, with 12 years of exclusivity, in a market where the off-label version it's replacing is \~34% of an $8.5B category.

Not financial advice. Do your own DD.

Sources used: [getfactd.io/report/us/OTLK](https://getfactd.ai/report/us/OTLK)